



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE	Application Number	09/739,843
	Filing Date	December 20, 2000
	First Named Inventor	Jerry L. NADLER et al.
	Group Art Unit	1642
	Examiner Name	Gary B. Nickol
	Attorney Docket Number	1954-363
Title of the Invention: <i>HUMAN LEUKOCYTE 12-LIPOXYGENASE AND ITS ROLE IN THE PATHOGENESIS OF DISEASE STATES</i>		

4
Jm
4/1/03

RESPONSE TO REQUIREMENT OF ELECTION OF SPECIES

RECEIVED

Assistant Commissioner for Patents
Washington, D.C. 20231


APR 01 2003

Dear Sir:

TECH CENTER 1600/2900

In response to the Office Action mailed March 10, 2003, Applicants elect the following species requested by the Office: inflammatory or autoimmune condition, atherosclerosis (claims 4 and 5) and vascular smooth muscle cells (claim 39). The Office has indicated that claims 4-5 and 39 are generic. Applicants respectfully submit that claim 3 also is generic to the elected species. Applicants now request favorable consideration of the above-identified patent application.

RESPECTFULLY SUBMITTED,					
NAME AND REG. NUMBER	Martha Cassidy Registration No. 44,066				
SIGNATURE				DATE	3/31/03
Address	Rothwell, Figg, Ernst & Manbeck Suite 800, 1425 K Street, N.W.				
City	Washington	State	D.C.	Zip Code	20005
Country	U.S.A.	Telephone	202-783-6040	Fax	202-783-6031



RECEIVED 9B
MAY 20 2002
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE	Application Number	09/739,843
	Filing Date	December 20, 2000
	First Named Inventor	Jerry L. NADLER et al.
	Group Art Unit	1617
	Examiner Name	Theodore J. Criares
	Attorney Docket Number	1954-363
Title of the Invention: <i>HUMAN LEUKOCYTE 12-LIPOXYGENASE AND ITS ROLE IN THE PATHOGENESIS OF DISEASE STATES</i>		

**RESPONSE TO RESTRICTION REQUIREMENT
AND PRELIMINARY AMENDMENT**

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

In response to the Office Action mailed March 27, 2002, Applicants elect the claims of Group II (claims 3-5), drawn to a method of diagnosing a disease state.

In the Claims:

Please cancel claims 1, 2, 10-21, 28, 32, 34-36 and 38, amend claim 3 as indicated below and add new claim 39.

3. (Amended) A method for diagnosing a disease state in a patient in which human 12-lipoxygenase, distinct from that found in human platelets and distinct from human 15-lipoxygenase, or 12-HETE is an etiological agent which comprises:

- B /
- (i) obtaining a physiological specimen from said patient; and
 - (ii) determining whether said etiological agent or antibodies to said etiological agent are present in said specimen.